• Tenectaplase versus Alteplase before Thrombectomy for Ischemic Stroke: EXTEND-IA TNK Trial

    EXTEND-IA TNK is a multicenter, randomized, open-label, blinded-outcomes, non-inferiority trial of acute ischemic stroke patients with internal carotid, middle cerebral, or basilar artery occlusion eligible for both intravenous thrombolysis. Patients were randomized 1:1 to receive IV tenecteplase (0.25mg/kg; max dose 25mg) or IV alteplase (0.9mg/kg; max dose 90mg). A blinded adaptive sample-size estimation helped determine the final sample size of 202. From 2015-2017, across 12 centers in Australia and New Zealand, 101 patients were assigned to each arm. The primary outcome of “substantial reperfusion” defined as reperfusion in >50% of the compromised vascular territory or the absence of the retrievable thrombus at the time of initial angiography was achieved in 22% of patients in tenectaplase group compared to 10% in alteplase group (p=0.002 for noninferiority; p=0.03 for superiority). At 90 days, patients in tenectaplase group had better functional status with median mRS of 2 compared to 3 in alteplase group (p=0.04). Symptomatic intracerebral hemorrhage occurred in one patient in each group. High fibrin specificity and longer half-life permitting bolus administration of the total dose, makes this genetically modified variant of alteplase a practical choice especially for inter-facility transfer patients. The EXTEND-IA TNK Part 2 studying the higher 0.4mg/kg tenectaplase dose and the TASTE trial comparing tenectaplase to alteplase in non-thrombectomy stroke patients would provide further information in near future. Current evidence suggests tenectaplase is a safe, effective and practical alternative to alteplase before thrombectomy in acute ischemic stroke patients.

    Source

    National Center for Biotechnology Information

We use cookies to improve the performance of our site, to analyze the traffic to our site, and to personalize your experience of the site. You can control cookies through your browser settings. Please find more information on the cookies used on our site here. Privacy Policy